Beijing Double-Crane Run-Chuang Technology

Beijing Double-Crane Run-Chuang Technology is the dedicated research and development subsidiary of China Resources Double-Crane Pharmaceutical (CR Double-Crane). Established to drive innovation within the group, the company focuses on the discovery and development of both innovative drugs and high-end generic medications. Its primary therapeutic areas of interest include cardiovascular health, nephrology, pediatrics, and oncology. The company gained significant attention for its role in the production and commercialization of Azvudine, an antiviral treatment for COVID-19, in collaboration with Genuine Biotech. Run-Chuang utilizes advanced platforms for small molecule synthesis and peptide development to maintain a robust pipeline of therapeutic candidates. It serves as the primary engine for CR Double-Crane's transition from a traditional pharmaceutical manufacturer to an innovation-driven healthcare provider.